1. Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate
   Darmadi Darmadi et al, 2023, F1000Research CrossRef
2. Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate
   Darmadi Darmadi et al, 2022, F1000Research CrossRef
3. FoxP3, PD-1 and CTLA-4 are decreased significantly after a tenofovir therapy in patients with chronic hepatitis B
   Hyosun Cho et al, 2020, Future Virology CrossRef
4. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) +49A>G (rs231775) gene polymorphism is not associated with COVID-19 severity and mortality in an Iranian population
   Ensie Sadat Mirsharif et al, 2024, Heliyon CrossRef
5. Association between CTLA4 + 49A/G polymorphism and risk of hepatocellular carcinoma: a systematic review and meta-analysis
   Xiujuan Tan et al, 2024, Nucleosides, Nucleotides & Nucleic Acids CrossRef
6. Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy
   Tung-Hung Su et al, 2018, The Journal of Infectious Diseases CrossRef
7. Association of CTLA4 c.49A > G (rs231775; p.Thr17Ala) gene variant with the risk of hepatocellular carcinoma and gastric cancer: A meta-analysis and meta-regression
   Akram Abbas El Awady et al, 2022, Meta Gene CrossRef
8. Computational analysis of structural and functional evaluation of the deleterious missense variants in the human CTLA4 gene
   Meryem Bouqdayr et al, 2023, Journal of Biomolecular Structure and Dynamics CrossRef
9. Circulating CTLA-4 levels and CTLA4 polymorphisms associate with disease condition and progression and hepatocellular carcinoma patients' survival in chronic hepatitis B virus infection
   Li Wang et al, 2020, International Immunopharmacology CrossRef
10. Polymorphisms rs231775 and rs5742909 CTLA-4 gene and their associative relations with chronic HBV infection in children
    F. I. Inoyatova et al, 2020, CHILDREN INFECTIONS CrossRef
11. Pemphigus vulgaris and pemphigus foliaceus determined by CD86 and CTLA4 polymorphisms
    Srdjan Tanasilovic et al, 2017, Clinics in Dermatology CrossRef
12. Host nucleotide polymorphism in hepatitis B virus-associated hepatocellular carcinoma
    Shilu Mathew et al, 2016, World Journal of Hepatology CrossRef
13. The study of immune checkpoint inhibitors in chronic hepatitis B virus infection
    Siyu Li et al, 2022, International Immunopharmacology CrossRef
14. Restoring homeostasis of CD4+T cells in hepatitis-B-virus-related liver fibrosis
    Li-Sha Cheng, 2015, World Journal of Gastroenterology CrossRef